| Ytd | -17.78% | |
| 1y | -32.17% |
| Open | 14.59 | Prev Close | 14.57 | Low | 14.30 | High | 14.80 | Mkt Cap | 11.16B |
| Vol | 3.84M | Avg Vol | 5.34M | EPS | -1.59 | P/E | N/A | Forward P/E | -12.53 |
| Beta | -1.31 | Short Ratio | 5.67 | Inst. Own | 15.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 16.86 | 200-d Avg | 17.70 | 1yr Est | 28.39 |
SMMT News
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c
As a result of such termination, no securities will be sold pursuant to the proposed underwritten pu
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering t
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") to
https://www.sec.gov/Archives/edgar/data/1599298/000119312526263861/d124326ds3asr.htm
Crude oil surged nearly 8% – its best day since April 2 – after US strikes on Iran and Tehran's
Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and